$DVA
DAVITA INC.

2020 Q4 Form 10-Q Financial Statement

#000092706620000215 Filed on October 29, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $2.905B $2.924B $2.899B
YoY Change 0.23% 0.69% 2.75%
Cost Of Revenue $2.057B $1.972B $2.001B
YoY Change 2.81% -0.98% -1.31%
Gross Profit $848.4M $952.3M $898.0M
YoY Change -5.52% 4.32% 13.08%
Gross Profit Margin 29.2% 32.57% 30.98%
Selling, General & Admin $304.5M $363.3M $278.4M
YoY Change 9.38% 21.63% 3.69%
% of Gross Profit 35.89% 38.15% 31.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $161.5M $156.8M $158.5M
YoY Change 1.89% 0.58% 2.19%
% of Gross Profit 19.04% 16.47% 17.65%
Operating Expenses $466.0M $520.2M $436.9M
YoY Change 6.66% 14.43% 3.12%
Operating Profit $381.7M $437.7M $462.6M
YoY Change -17.49% 15.68% 19.25%
Interest Expense -$61.30M -$68.20M -$90.60M
YoY Change -32.34% -19.48% -34.77%
% of Operating Profit -16.06% -15.58% -19.59%
Other Income/Expense, Net $6.200M $5.395M $11.50M
YoY Change -46.09% 2.18% -2400.0%
Pretax Income $327.4M $283.3M $382.0M
YoY Change -14.29% 3.49% 47.43%
Income Tax $73.40M $65.79M $81.70M
% Of Pretax Income 22.42% 23.22% 21.39%
Net Earnings $173.8M $158.7M $244.9M
YoY Change -29.03% 10.75% -263.5%
Net Earnings / Revenue 5.98% 5.43% 8.45%
Basic Earnings Per Share $1.56 $1.31 $1.89
Diluted Earnings Per Share $1.50 $1.28 $1.88
COMMON SHARES
Basic Shares Outstanding 112.0M shares 120.9M shares 129.7M shares
Diluted Shares Outstanding 124.0M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $377.3M $759.7M $1.150B
YoY Change -67.21% -45.3% 218.34%
Cash & Equivalents $325.0M $710.5M $1.102B
Short-Term Investments $52.29M $49.23M $48.09M
Other Short-Term Assets $253.0M $165.0M $173.0M
YoY Change 46.24% 6.45% -96.91%
Inventory $111.6M $106.3M $97.95M
Prepaid Expenses
Receivables $1.824B $1.804B $1.796B
Other Receivables $544.4M $548.4M $489.7M
Total Short-Term Assets $3.149B $3.430B $3.690B
YoY Change -14.67% -14.23% -56.2%
LONG-TERM ASSETS
Property, Plant & Equipment $3.522B $3.418B $3.473B
YoY Change 1.39% -0.04% 2.35%
Goodwill $6.919B $6.868B $6.788B
YoY Change 1.94% 1.52% -0.79%
Intangibles $166.6M $118.1M $135.7M
YoY Change 22.77% 0.35% 14.17%
Long-Term Investments $290.0M $282.0M $0.00
YoY Change 11.02%
Other Assets $79.50M $96.11M $116.0M
YoY Change -31.45% -16.31% 62.01%
Total Long-Term Assets $13.84B $13.62B $13.62B
YoY Change 1.6% 1.22% 27.47%
TOTAL ASSETS
Total Short-Term Assets $3.149B $3.430B $3.690B
Total Long-Term Assets $13.84B $13.62B $13.62B
Total Assets $16.99B $17.05B $17.31B
YoY Change -1.87% -2.32% -9.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $434.3M $388.5M $403.8M
YoY Change 7.53% 16.97% -12.83%
Accrued Expenses $1.055B $1.067B $1.039B
YoY Change 1.54% 2.89% 57.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $169.0M $164.0M $131.0M
YoY Change 29.01% 35.54% -93.21%
Total Short-Term Liabilities $2.476B $2.499B $2.372B
YoY Change 4.39% 13.26% -51.5%
LONG-TERM LIABILITIES
Long-Term Debt $7.917B $7.867B $7.978B
YoY Change -0.76% -1.83% -2.39%
Other Long-Term Liabilities $150.1M $147.4M $160.8M
YoY Change -6.68% 9.09% -64.32%
Total Long-Term Liabilities $150.1M $147.4M $160.8M
YoY Change -6.68% 9.09% -64.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.476B $2.499B $2.372B
Total Long-Term Liabilities $150.1M $147.4M $160.8M
Total Liabilities $14.09B $13.99B $13.81B
YoY Change 2.03% 2.54% -1.89%
SHAREHOLDERS EQUITY
Retained Earnings $852.5M $2.032B $1.432B
YoY Change -40.45% -39.34% -47.81%
Common Stock $597.2M $694.3M $749.2M
YoY Change -20.29% -23.47% -24.72%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $1.029B $0.00
YoY Change -44.7%
Treasury Stock Shares
Shareholders Equity $1.384B $1.575B $2.133B
YoY Change
Total Liabilities & Shareholders Equity $16.99B $17.05B $17.31B
YoY Change -1.87% -2.32% -9.41%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income $173.8M $158.7M $244.9M
YoY Change -29.03% 10.75% -263.5%
Depreciation, Depletion And Amortization $161.5M $156.8M $158.5M
YoY Change 1.89% 0.58% 2.19%
Cash From Operating Activities $484.8M $482.7M $680.6M
YoY Change -28.77% -24.66% 62.4%
INVESTING ACTIVITIES
Capital Expenditures -$224.6M -$158.2M -$219.3M
YoY Change 2.42% -191.31% -22.07%
Acquisitions
YoY Change
Other Investing Activities -$113.4M $78.10M $80.70M
YoY Change -240.52% -181.87% -228.5%
Cash From Investing Activities -$338.1M -$80.20M -$138.7M
YoY Change 143.76% -70.15% -59.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -465.1M -2.621B -692.7M
YoY Change -32.86% -2.67% 242.75%
NET CHANGE
Cash From Operating Activities 484.8M 482.7M 680.6M
Cash From Investing Activities -338.1M -80.20M -138.7M
Cash From Financing Activities -465.1M -2.621B -692.7M
Net Change In Cash -318.4M -2.219B -150.8M
YoY Change 111.14% -4.41% 18.46%
FREE CASH FLOW
Cash From Operating Activities $484.8M $482.7M $680.6M
Capital Expenditures -$224.6M -$158.2M -$219.3M
Free Cash Flow $709.4M $640.9M $899.9M
YoY Change -21.17% 37.11% 28.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Profit Loss
ProfitLoss
760307000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Entity Central Index Key
EntityCentralIndexKey
0000927066
dva Corporate Integrity Agreement Period
CorporateIntegrityAgreementPeriod
P5Y
CY2019Q4 dva Terminated Remaining Prior Share Repurchases Authorized Amount
TerminatedRemainingPriorShareRepurchasesAuthorizedAmount
246373000 USD
dva Valuation Adjustment
ValuationAdjustment
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125842853 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126065294 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125842853 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113781317 shares
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
81922000 USD
CY2020Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
75727000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
3969566000 USD
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Property Plant And Equipment Owned Accumulated Depreciation
PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
4368659000 USD
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0 shares
CY2020Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12283977 shares
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
1-14106
dei Entity Registrant Name
EntityRegistrantName
DAVITA INC.
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
51-0354549
dei Entity Address Address Line1
EntityAddressAddressLine1
2000 16th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Denver,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80202
dei City Area Code
CityAreaCode
720
dei Local Phone Number
LocalPhoneNumber
631-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112000000.0 shares
CY2020Q3 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2781650000 USD
CY2019Q3 dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
2777192000 USD
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
8253128000 USD
dva Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts
RevenueFromContractWithCustomerIncludingAssessedTaxNetOfProvisionForUncollectibleAccounts
8130697000 USD
CY2020Q3 us-gaap Other Income
OtherIncome
142416000 USD
CY2019Q3 us-gaap Other Income
OtherIncome
126886000 USD
us-gaap Other Income
OtherIncome
392154000 USD
us-gaap Other Income
OtherIncome
359198000 USD
CY2020Q3 us-gaap Revenues
Revenues
2924066000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
us-gaap Revenues
Revenues
8645282000 USD
us-gaap Revenues
Revenues
8489895000 USD
CY2020Q3 dva Patient Care Costs
PatientCareCosts
1971719000 USD
CY2019Q3 dva Patient Care Costs
PatientCareCosts
1991172000 USD
dva Patient Care Costs
PatientCareCosts
5931732000 USD
dva Patient Care Costs
PatientCareCosts
5913860000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
363280000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
298736000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
943065000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
824887000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
156894000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155915000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
468949000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
456685000 USD
CY2020Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
5496000 USD
CY2019Q3 us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
0 USD
us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
-16252000 USD
CY2019Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3936000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
27681000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11158000 USD
CY2020Q3 us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
0 USD
us-gaap Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee
GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
273785000 USD
CY2020Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
86074000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
89022000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
990891000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
813416000 USD
CY2019Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
83855000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
124892000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
2486397000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
2525742000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7332317000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7309166000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
437669000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378336000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1312965000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
CY2020Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73658000 USD
CY2019Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
88589000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
243642000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
351774000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5395000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5280000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10590000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
283332000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65792000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65254000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
240564000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
197938000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
217540000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
208531000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
750327000 USD
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
615478000 USD
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6843000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
9980000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
217540000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
us-gaap Profit Loss
ProfitLoss
760307000 USD
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.72
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.87
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.50
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120905038 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150675465 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122582099 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161147122 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123953879 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151295950 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124927380 shares
us-gaap Profit Loss
ProfitLoss
718332000 USD
CY2020Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
58866000 USD
CY2019Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
58418000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
160438000 USD
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
152222000 USD
CY2020Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
158674000 USD
CY2019Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
143270000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
599869000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
566110000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.31
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.81
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.88
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.51
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.28
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.99
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161636011 shares
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
158674000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
150113000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
589889000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
464590000 USD
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-6843000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
9980000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
101520000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
158674000 USD
us-gaap Net Income Loss
NetIncomeLoss
599869000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
143270000 USD
us-gaap Net Income Loss
NetIncomeLoss
566110000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
217540000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
201688000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
152222000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1628000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1060000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-16470000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
-1672000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1034000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-1569000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-4280000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
-4782000 USD
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
13171000 USD
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-44502000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-62842000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-45790000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
12577000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43993000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-75032000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42680000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
230117000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
157695000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
685275000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
675652000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
58866000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
58418000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
160438000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
171251000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
99277000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
524837000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
523430000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
710514000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1102372000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
106823000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
106346000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19360000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11572000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1804390000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1795598000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
106254000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
97949000 USD
CY2020Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
548381000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
489695000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
365190000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
343912000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
58512000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
66866000 USD
CY2020Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
75441000 USD
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
19772000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
3429675000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3690170000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3417919000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3473384000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2834163000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2830047000 USD
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
118078000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
135684000 USD
CY2020Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
252483000 USD
CY2019Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
241983000 USD
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
29867000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36519000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
96110000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
115972000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
6868377000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
6787635000 USD
CY2020Q3 us-gaap Assets
Assets
17046672000 USD
CY2019Q4 us-gaap Assets
Assets
17311394000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
388504000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
403840000 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
879792000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
756174000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
701968000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
695052000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
163787000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
130708000 USD
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
42412000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2499241000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2372098000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2710550000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2723800000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7866545000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7977526000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
160809000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
147371000 USD
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
765691000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
577543000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
13989398000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
13811776000 USD
CY2020Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1303934000 USD
CY2019Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
1180376000 USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
126000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
126000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
694132000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
749043000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2031607000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1431738000 USD
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1028578000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-122530000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-47498000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1574757000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
2133409000 USD
CY2020Q3 us-gaap Minority Interest
MinorityInterest
178583000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
185833000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1753340000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
2319242000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17046672000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17311394000 USD
us-gaap Profit Loss
ProfitLoss
760307000 USD
us-gaap Profit Loss
ProfitLoss
718332000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
468949000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
456685000 USD
dva Debt Refinancing Charges
DebtRefinancingCharges
86957000 USD
dva Debt Refinancing Charges
DebtRefinancingCharges
33402000 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
124892000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
67217000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
47811000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
191783000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
72590000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-3026000 USD
dva Adjustment Income Loss From Equity Method Investments
AdjustmentIncomeLossFromEquityMethodInvestments
-5131000 USD
dva Gain Loss On Disposition Of Business Interests Before Tax
GainLossOnDispositionOfBusinessInterestsBeforeTax
-16252000 USD
dva Gain Loss On Disposition Of Business Interests Before Tax
GainLossOnDispositionOfBusinessInterestsBeforeTax
-23022000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7980000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-24291000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
98322000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
3927411000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12405000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
182684000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8445000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9519000 USD
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
62025000 USD
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-51319000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1853000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2324000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
445000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-106662000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-12124000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-57930000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
123833000 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
140046000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-100160000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
57279000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-19547000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-27542000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1494230000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1391825000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
449896000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
112597000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
77348000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
83339000 USD
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
3863619000 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
147829000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3388000 USD
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5160000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
148341000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
3434000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5893000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
9613000 USD
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8770000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
902000 USD
us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
1296000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-487307000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3134025000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3826484000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
38519991000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-16606000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4178000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1357141000 USD
us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
40485415000 USD
dva Debt Financing And Debt Redemption Costs
DebtFinancingAndDebtRedemptionCosts
105705000 USD
dva Debt Financing And Debt Redemption Costs
DebtFinancingAndDebtRedemptionCosts
84588000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1025878000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1837022000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
179098000 USD
us-gaap Payments Of Distributions To Affiliates
PaymentsOfDistributionsToAffiliates
157170000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
3838000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
7333000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
32854000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
44095000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
6782000 USD
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
10988000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1381698000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4003764000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-391381000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
517908000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1208718000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
415420000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
817337000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8328000 USD
CY2020Q3 us-gaap Revenues
Revenues
2924066000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
9980000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
us-gaap Revenues
Revenues
8645282000 USD
us-gaap Revenues
Revenues
8489895000 USD
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
101520000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
120905000 shares
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
0 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-6843000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
158674000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
150113000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
589889000 USD
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
464590000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
158674000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
143270000 USD
us-gaap Net Income Loss
NetIncomeLoss
599869000 USD
us-gaap Net Income Loss
NetIncomeLoss
566110000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
150675000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
122582000 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
161147000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3049000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
621000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2345000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
489000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123954000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
151296000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124927000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161636000 shares
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.31
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
1.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
4.81
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
2.88
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.05
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.08
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.63
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.51
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
1.28
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.99
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
4.72
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
2.87
CY2020Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0
CY2019Q3 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.04
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.08
us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
0.63
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.50
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2765000 shares
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7293000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3063000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6414000 shares
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8212000 USD
CY2020Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
41015000 USD
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
49227000 USD
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8140000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
39951000 USD
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
48091000 USD
CY2020Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8212000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19360000 USD
CY2019Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8140000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11572000 USD
CY2020Q3 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
29867000 USD
CY2019Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
0 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
36519000 USD
CY2020Q3 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8212000 USD
CY2020Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
41015000 USD
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
49227000 USD
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
8140000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
39951000 USD
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
48091000 USD
CY2020Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
252483000 USD
CY2019Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
241983000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
27681000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
11158000 USD
dva Valuation Adjustment
ValuationAdjustment
0 USD
CY2018Q4 us-gaap Goodwill
Goodwill
6841960000 USD
CY2019 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
90226000 USD
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
124892000 USD
CY2019 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
19659000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
6787635000 USD
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
110248000 USD
us-gaap Goodwill Written Off Related To Sale Of Business Unit
GoodwillWrittenOffRelatedToSaleOfBusinessUnit
8293000 USD
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
21213000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
6868377000 USD
CY2020Q3 us-gaap Goodwill Gross
GoodwillGross
6998809000 USD
CY2020Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
130432000 USD
CY2020Q3 us-gaap Goodwill
Goodwill
6868377000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
70129000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
65883000 USD
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
1915000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
68214000 USD
CY2020Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
16961000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
14428000 USD
CY2020Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8111277000 USD
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
8181074000 USD
CY2020Q3 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
80945000 USD
CY2019Q4 dva Discount And Deferred Finance Costs
DiscountAndDeferredFinanceCosts
72840000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8030332000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
8108234000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
163787000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
130708000 USD
CY2020Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7866545000 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
7977526000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
52092000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
148821000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
170566000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
228303000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1421461000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
63571000 USD
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
6026463000 USD
CY2020Q3 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0331
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0376
CY2020Q3 us-gaap Longterm Debt Weighted Average Interest Rate
LongtermDebtWeightedAverageInterestRate
0.0311
CY2020Q3 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
0.45
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
64634000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> suits, governmental investigations and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Governmental Inquiries and Certain Related Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Texas Investigation</span><span style="font-family:inherit;font-size:10pt;">: In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In connection with the Company’s ongoing efforts working with the government, the Company learned that a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaint had been filed covering some of the issues in the CID and practices that had been identified by the Company in a self-disclosure filed with the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) in February 2016. In December 2017, the Company finalized and executed a settlement agreement with the government and relators in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> matter that included total monetary consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$63,700</span></span><span style="font-family:inherit;font-size:10pt;">, as previously disclosed, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$41,500</span></span><span style="font-family:inherit;font-size:10pt;"> was an incremental cash payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$22,200</span></span><span style="font-family:inherit;font-size:10pt;"> was for amounts previously refunded, and all of which was previously accrued. The government’s investigation into certain of the Company's relationships with pharmaceutical manufacturers is ongoing, and in July 2018 the OIG served the Company with a subpoena seeking additional documents and information relating to those relationships. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Colorado Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018 and May 2019, the Company received a CID pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. On September 30, 2019, the U.S. Attorney’s Office notified the U.S. District Court, Middle District of Florida, of its decision not to elect to intervene at this time in the matter of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. ex rel. Lorne Holland, et al. v. DaVita Healthcare Partners, Inc., et al</span><span style="font-family:inherit;font-size:10pt;">. The court then unsealed the complaint, which alleges violations of the FCA, by order dated the same day. In January 2020, the private party relators served the Company and DaVita Labs with an amended complaint. On February 24, 2020, the Company and DaVita Labs filed a motion to dismiss the amended complaint. On June 25, 2020, the court denied the motion to dismiss. The Company and DaVita Labs answered the complaint on July 23, 2020. The Company and DaVita Labs dispute these allegations and intend to defend this action accordingly.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2020 U.S. Attorney New Jersey Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2020, the U.S. Attorney’s Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney’s Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company’s joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity Agreement, the term of which expired </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">October 22, 2019</span></span></span><span style="font-family:inherit;font-size:10pt;">. The Company is cooperating with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2020 California Department of Insurance Investigation</span><span style="font-family:inherit;font-size:10pt;">: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020. The subpoena, as revised, requests information on a number of topics, including but not limited to the Company’s communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients’ decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is cooperating with CDI in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2020 Department of Justice Investigation</span><span style="font-family:inherit;font-size:10pt;">: In October 2020, the Company received a CID from the Department of Justice pursuant to a False Claims Act investigation concerning allegations that DaVita Medical Group (DMG) may have submitted undocumented or unsupported diagnosis codes in connection with Medicare Advantage beneficiaries. The CID covers the period from January 1, 2015 through June 19, 2019, the date the Company completed the divestiture of DMG to Collaborative Care Holdings, LLC. The Company is cooperating with the government in this investigation.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies and/or private civil </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder and Derivative Claims</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." In November 2017, the Court appointed the lead plaintiff and an amended complaint was filed on January 12, 2018. On March 27, 2018, the Company and various individual defendants filed a motion to dismiss. On March 28, 2019, the U.S. District Court for the District of Colorado denied the motion to dismiss. The Company answered the complaint on May 28, 2019. On January 31, 2020, the plaintiffs filed a motion for class certification and the Company filed its opposition on June 29, 2020. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the Company continues to dispute the allegations, in July 2020, it reached an agreement in principle to resolve this matter without admitting to any liability. Settlement of this matter on the agreed terms is expected to be covered primarily with insurance proceeds, with the Company contributing an amount that would not have a material impact on the Company’s consolidated financial position, results of operations or cash flows. A motion for preliminary approval of the settlement was granted by the Court on October 27, 2020. The settlement is subject to, among other things, final approval by the Court.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="font-family:inherit;font-size:10pt;">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. An amended complaint was filed in September 2017, and on December 18, 2017, the Company filed a motion to dismiss and a motion to stay proceedings in the alternative. On April 25, 2019, the court denied the Company's motion to dismiss. The Company answered the complaint on May 28, 2019.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While the defendants continue to dispute the allegations, in July 2020, an agreement in principle was reached to resolve this matter without admitting to any liability. The Company’s Board of Directors (Board) approved the settlement on October 20, 2020. The settlement is now subject to, among other things, approval by the Court. A motion for preliminary approval of the settlement was filed on October 23, 2020. As part of the settlement, the Company agreed to certain corporate governance policies, but will not make any financial contribution towards the settlement.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</span></div><div style="line-height:120%;padding-top:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * *</span></div><div style="line-height:120%;padding-top:12px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note </span><span style="font-family:inherit;font-size:10pt;">9</span><span style="font-family:inherit;font-size:10pt;"> to these condensed consolidated financial statements, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.</span></div>
dva Corporate Integrity Agreement Expiration Date
CorporateIntegrityAgreementExpirationDate
2019-10-22
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
74492000 USD
dva Longterm Incentive Program Compensation Cost
LongtermIncentiveProgramCompensationCost
82469000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
8794000 USD
dva Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense
6798000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
207513000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
dva Longterm Incentive Compensation Cash Awards Number Of Awards Outstanding
LongtermIncentiveCompensationCashAwardsNumberOfAwardsOutstanding
0
dva Longterm Incentive Program Awards Compensation Cost
LongtermIncentiveProgramAwardsCompensationCost
66302000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
5049000 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
2791000 USD
CY2020Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
8232000 shares
CY2019Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
30592000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
12284000 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
32652000 shares
CY2020Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
725439000 USD
CY2019Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1747968000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1028578000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1860157000 USD
CY2020Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
88.13
CY2019Q3 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
57.14
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
83.73
us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
56.97
CY2019Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
2000000000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
24057000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
24586000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
5815000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
11676000 USD
CY2020Q3 dva Foreign Currency Translation Adjustment For Contingent Earn Out Obligations
ForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations
975000 USD
dva Foreign Currency Translation Adjustment For Contingent Earn Out Obligations
ForeignCurrencyTranslationAdjustmentForContingentEarnOutObligations
6358000 USD
CY2020Q3 dva Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss
BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
1990000 USD
dva Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss
BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss
2630000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
593000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
960000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
26314000 USD
CY2020Q3 us-gaap Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High
BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
26314000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
4465476000 USD
CY2019Q2 us-gaap Proceeds From Divestiture Of Businesses Net Of Cash Divested
ProceedsFromDivestitureOfBusinessesNetOfCashDivested
3824509000 USD
CY2020Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
0 USD
CY2019Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-6843000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
9980000 USD
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
102854000 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
0 USD
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
97005000 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0 USD
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
-43442000 USD
CY2020Q3 us-gaap Revenues
Revenues
2924066000 USD
CY2020Q3 dva Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average Ebitda Multiple
PotentialIncreaseDecreaseInFairValueOfNoncontrollingInterestsDueToChangeInWeightedAverageEBITDAMultiple
150000000 USD
CY2019Q3 us-gaap Revenues
Revenues
2904078000 USD
us-gaap Revenues
Revenues
8645282000 USD
us-gaap Revenues
Revenues
8489895000 USD
CY2020Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
25841000 USD
CY2019Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
24681000 USD
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
122514000 USD
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
65546000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
437669000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378336000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1312965000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
1180729000 USD
CY2020Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
73658000 USD
CY2019Q3 us-gaap Interest And Debt Expense
InterestAndDebtExpense
88589000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
243642000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
351774000 USD
CY2020Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
86074000 USD
CY2019Q3 dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
21242000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
89022000 USD
dva Debt Prepayment Refinancing Redemption Charges
DebtPrepaymentRefinancingRedemptionCharges
33402000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5395000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5280000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10590000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17863000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
283332000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
273785000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
990891000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
813416000 USD
CY2020Q3 us-gaap Assets
Assets
17046672000 USD
CY2019Q4 us-gaap Assets
Assets
17311394000 USD
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
156894000 USD
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
155915000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
468949000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
456685000 USD
CY2020Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
0 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent
202000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
449896000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547183000 USD
CY2020Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
158674000 USD
CY2019Q3 us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
143270000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
599869000 USD
us-gaap Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
566110000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
4197000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
10732000 USD
CY2020Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
0 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
-202000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
4197000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesNet
10732000 USD
CY2020Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
158674000 USD
CY2019Q3 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
143068000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
604066000 USD
us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet
576842000 USD
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">New accounting standards</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">New standards recently adopted</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. </span><span style="font-family:inherit;font-size:10pt;">The amendments in this ASU amend the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments and off-balance sheet credit exposures. The amendment requires entities to consider a broader range of information to estimate expected credit losses, which may result in earlier recognition of losses. The amendments in this ASU became effective for the Company beginning on January 1, 2020 and were applied using a modified retrospective basis. The adoption of ASU No. 2016-13 did not have a material impact on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework -Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:inherit;font-size:10pt;">. The applicable amendments in this ASU remove </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requirements for disclosures concerning transfers between fair value measurement levels 1, 2 and 3 and disclosures concerning valuation processes for level 3 fair value measurements. The applicable amendments in this ASU also add a requirement to separately disclose the changes in unrealized gains and losses included in other comprehensive income for the reporting period for level 3 items measured at fair value on a recurring basis, and require disclosure of the range and weighted average of significant unobservable inputs used to develop level 3 fair value measurements. The amendments in this ASU became effective for the Company beginning on January 1, 2020 and were applied on a prospective basis. The adoption of this ASU did not have a material impact on the Company’s consolidated financial statements when adopted January 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. ASU No. 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this ASU as of January 1, 2020, using the prospective transition approach, which allows the Company to change the accounting method without restating prior periods or booking cumulative adjustments. The adoption of ASU No. 2018-15 did not have a material impact on the Company's consolidated financial statements. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">New standards not yet adopted</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">. ASU No. 2019-12 attempts to simplify aspects of accounting for franchise taxes and enacted changes in tax laws or rates, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. ASU No. 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted for all entities. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.</span><span style="font-family:inherit;font-size:10pt;"> ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. generally accepted accounting principles to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company may elect to apply the amendments prospectively through December 31, 2022. The Company is currently assessing the effect this guidance may have on its consolidated financial statements.</span></div>

Files In Submission

Name View Source Status
0000927066-20-000215-index-headers.html Edgar Link pending
0000927066-20-000215-index.html Edgar Link pending
0000927066-20-000215.txt Edgar Link pending
0000927066-20-000215-xbrl.zip Edgar Link pending
dva-20200930.xsd Edgar Link pending
dva-20200930_cal.xml Edgar Link unprocessable
dva-20200930_def.xml Edgar Link unprocessable
dva-20200930_lab.xml Edgar Link unprocessable
dva-20200930_pre.xml Edgar Link unprocessable
dva-9302010q.htm Edgar Link pending
dva-9302010q_htm.xml Edgar Link completed
dva-93020ex104.htm Edgar Link pending
dva-93020ex31110xq.htm Edgar Link pending
dva-93020ex31210xq.htm Edgar Link pending
dva-93020ex32110xq.htm Edgar Link pending
dva-93020ex32210xq.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logoa32.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending